Thursday, September 24, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Marketseli lillycvstirzepatideaccess

CVS and Eli Lilly strike partnership on GLP-1 access

The deal was announced alongside second-quarter results in which both companies exceeded Wall Street expectations.

TR
By Tom Reyes · Markets Editor
Aug 5 03:00 ETSource: Yahoo Finance

The wire

  1. 01CVS and Eli Lilly said they formed a partnership aimed at improving access to GLP-1 medicines, disclosed as both companies topped second-quarter estimates.
  2. 02Pharmacy and telehealth operators watch payer-manufacturer arrangements closely because they shape formulary placement and cash-pay pricing for semaglutide and tirzepatide alternatives.
  3. 03Terms, covered products and start date were not detailed in the report.

From the source

CVS, Eli Lilly Forge Partnership on Improved GLP-1 Access; Companies Top Second-Quarter Views

Read at finance.yahoo.com
PeptiPrescribed peptides from $99/moSee all →